Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy

Launched by ENDEAVOR HEALTH · Mar 16, 2022

Keywords

ClinConnect Summary

This clinical trial is investigating how well a new inherited risk assessment test can predict prostate cancer in men who are undergoing a prostate biopsy. A prostate biopsy is a procedure where a small sample of tissue from the prostate gland is taken to check for cancer. The goal is to see if this test can help identify men who are more likely to have prostate cancer based on their genetic background.

To participate in this study, men aged 40 to 69 who are having a prostate biopsy and have a prostate-specific antigen (PSA) level between 2.5 and 10 ng/mL may be eligible. The trial is open to men from four different ethnic backgrounds: Caucasian, African American, East Asian, and Latino. However, men who have been previously diagnosed with prostate cancer or have had PSA test results outside the specified range cannot participate. Participants can expect to undergo the biopsy and the risk assessment test, which may help doctors better understand their chances of having prostate cancer. This research is important as it could potentially lead to more personalized and effective ways to manage prostate cancer risk for men in the future.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Consecutive patients undergoing prostate biopsy for detection of prostate cancer
• • Aged 40 to 69 years
• • Four ethnicity groups (Caucasian, African Americans, East Asians, Latinos)
• • PSA between 2.5-10 ng/mL
• Exclusion Criteria:
• • Previous diagnosis of prostate cancer.
• • Ethnicity outside the inclusion criterion (including mixed ethnicity).
• • Any prior PSA test result outside the range of inclusion criterion.